Dialysis company shares plunge after Ozempic trial success vs. kidney trouble

The trial success of Novo Nordisk’s hit drug against kidney failure sent shares of a German kidney dialysis services firm plummeting on Wednesday. Fresenius Medical Care shares FME, FMS, slumped 23%, and shares of its part owner Fresenius FRE, lost 12%, after Novo Nordisk halted a trial of…#novonordisks #freseniusmedicalcare #fme #fms #freseniusfre #novonordisk #nvs #copenhagen #danish #nestle
Source: Reuters: Health - Category: Consumer Health News Source Type: news